Enp2/NOL10 expression had a significant effect in prostate cancer prognosis and severity (96); NOL10 is frequently mutated in specific cancers (4% in endometrial cancers cf. BioPortal) and is a critical dependency in some acute myeloid leukemias (97). This evidence concerns the gene NOL10 and prostate carcinoma.